Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP) (HPV-AMP)

Regional University Hospital Center (CHRU)

Status: Enrolling

Conditions: Human Papilloma Virus; Infertility, Female

Study type: Observational

Funder types: Other

Identifiers

NCT06550531

29BRC21.0363 - HPV AMP

Details and patient eligibility

About

The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Full description

This is a single-center prospective study in the assisted reproduction center of Brest University Hospital. All new patients coming to consult will be offered participation in the study. The HPV test will be updated if it is older than 12 months. We will analyze stimulation results and pregnancy outcomes according to HPV status. Inclusions will take place over 3 years

Enrollment: 618 estimated patients

Sex: Female

Ages: 25 to 38 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all etiology of infertility AMH > ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months

Exclusion criteria

Age < 25 y Age > ou = 38 y AMH < 1.1 ng/ml patient under juridic protection rejection of participation